Alex Michael Azar II (born June 17, 1967) is an American lawyer, business executive and former government official who served as the 24th United States Secretary of Health and Human Services. His career has alternated between public service at the Department of Health and Human Services and senior positions in the pharmaceutical sector. Azar's background and decisions at HHS drew attention for their intersection of government health policy, industry experience and the federal response to public-health challenges.

Early life and education

Azar grew up in the United States and completed undergraduate and law studies before beginning a career that combined legal work and public administration. He earned degrees from nationally recognized institutions and trained as an attorney, which prepared him for regulatory and policy roles at the federal level. His legal background shaped his approach to rulemaking and enforcement in later administrative positions.

Government service

Azar first served in senior roles at the Department of Health and Human Services, including an executive post during the administration of President George W. Bush. From 2005 to 2007 he was the United States Deputy Secretary of Health and Human Services, a role in which he was involved with departmental operations, program oversight and legal matters affecting federal health programs. Years later, President Donald Trump nominated him to lead HHS; the Senate confirmed his appointment and he assumed office in early 2018.

Private-sector career and biotech ties

Between stints in government, Azar held executive positions in the pharmaceutical industry. He served as president of a major drug manufacturer from 2012 to 2017, a period when the company expanded its research, development and commercial activities. During this time he was also associated with industry groups and served on boards connected to biotechnology and pharmaceutical trade, which later became a focal point in discussions about conflicts of interest and the relationship between regulators and industry.

Tenure as HHS Secretary (2018–2021)

President Donald Trump nominated Azar to be Secretary of the Department of Health and Human Services; the U.S. Senate confirmed him, and he led the department from January 29, 2018 to January 20, 2021. As HHS Secretary he oversaw agencies that administer public-health programs, regulatory functions and medical research. His time in office included efforts to reshape regulatory priorities, promote certain market-oriented reforms, and coordinate parts of the federal response to the COVID-19 pandemic. Observers and stakeholders praised some administrative changes while criticizing others, especially where industry ties were perceived to influence policy.

Policies, criticisms and legacy

  • Supporters noted Azar's emphasis on innovation, streamlining regulation and advancing biomedical research priorities within the Department of Health and Human Services.
  • Critics pointed to his former leadership role at Eli Lilly and his association with industry groups such as the Biotechnology Innovation Organization—on whose board he served—as reasons to question potential conflicts; he appeared on the board of the Biotechnology Innovation Organization prior to becoming Secretary.
  • Throughout his career he advocated for policies favoring private-sector solutions and competition in drug development and distribution, positions that informed debates about drug pricing and access.

Notable facts and distinctions

Earlier in his career Azar worked within the HHS legal and executive structure, serving in roles that bridged law, policy and administration. His experience as both a senior government official and a pharmaceutical executive makes him a frequently cited example in discussions about the movement of professionals between industry and public service. After leaving office with the change of administration on January 20, 2021, commentators and analysts assessed his legacy in terms of departmental priorities, pandemic management, and the ongoing conversation about drug costs and regulation.

Further reading on Azar's public statements, official initiatives and post-government activities can be found through primary sources and reputable news coverage. For context on the agencies and organizations mentioned above, see the Department of Health and Human Services (HHS), historical accounts of the Bush-era administration in which he served as deputy (George W. Bush administration), corporate histories of his time at Eli Lilly (Eli Lilly) and industry perspectives represented by trade organizations such as BIO. Official nomination and confirmation records are available through records of the United States Senate and announcements from the office of the President.